Madrigal Pharmaceuticals financials
$509.44−1.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $364.3M | $311.3M | $321.1M | $287.3M | $212.8M | $137.3M | $103.3M | $62.2M | $14.6M | $0.00 | $0.00 | $0.00 |
| Gross profit | $364.3M | $284.5M | $321.1M | $287.3M | $212.8M | $132.7M | $103.3M | $62.2M | $14.6M | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 91.4% | 100.0% | 100.0% | 100.0% | 96.7% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating income | -$56.3M | -$92.7M | -$59.6M | -$114.0M | -$47.2M | -$79.3M | -$67.0M | -$116.3M | -$162.5M | -$152.0M | -$117.2M | -$98.5M |
| Net income | -$57.9M | -$94.4M | -$58.6M | -$114.2M | -$42.3M | -$73.2M | -$59.4M | -$107.0M | -$152.0M | -$147.5M | -$112.2M | -$98.7M |
| Net margin | −15.9% | −30.3% | −18.2% | −39.8% | −19.9% | −53.4% | −57.5% | −172.0% | −1038.2% | — | — | — |
| Diluted EPS | $-1.99 | $-3.25 | $-5.36 | $-5.08 | $-1.50 | $-2.61 | $-2.71 | $-4.92 | $-7.10 | $-7.38 | $-5.67 | $-5.34 |
| EBITDA | -$55.9M | -$92.3M | -$59.2M | -$113.6M | -$46.8M | -$78.9M | -$66.6M | -$116.0M | -$162.3M | -$151.9M | -$117.2M | -$98.4M |
| Operating cash flow | $23.3M | -$167.4M | -$133.5M | $79.8M | -$47.1M | -$88.9M | -$104.5M | -$67.0M | -$134.9M | -$149.2M | -$79.9M | -$84.9M |
| Free cash flow | $19.1M | -$171.3M | -$133.8M | $79.0M | -$47.1M | -$88.9M | -$104.7M | -$67.8M | -$135.1M | -$149.5M | -$81.0M | -$85.3M |
| Diluted shares | 29.1M | 29.0M | 10.9M | 22.5M | 28.2M | 28.1M | 21.9M | 21.7M | 21.4M | 20.0M | 19.8M | 18.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $292.7M | $227.0M | $198.7M | $295.7M | $186.2M | $183.6M |
| Short-term investments | $546.0M | $585.7M | $784.9M | $814.1M | $610.8M | $659.4M |
| Total debt | $340.8M | $340.3M | $339.9M | $339.8M | $118.4M | $118.0M |
| Total assets | $1.24B | $1.23B | $1.26B | $1.36B | $1.02B | $996.6M |
| Total liabilities | $720.9M | $683.9M | $656.9M | $736.7M | $319.4M | $286.0M |
| Shareholders' equity | $523.7M | $543.5M | $602.7M | $625.7M | $696.0M | $710.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology